They found a statistical trend towards a higher number of events in the ≥50% dose relative to the <50 dose group (54.2% vs. 50.8%, P = 0.10). 22 In a similar line, we found a poorer outcome among those CCS patients on the higher beta-blocker dose relative to dose not on beta-blocker.
A nonsignificant trend towards benefit of beta-blockers appeared during the first year in patients with mildly reduced LVEF (41–49%), whereas in the CCS phase, higher beta-blocker doses were associated with worse outcomes.
In this group, beta-blocker therapy was associated with a numerically lower incidence of events compared with no beta-blocker therapy, although this difference did not reach statistical significance, likely due to the size of the subgroups.